Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Nikhil-Chopra"

30 News Found

Medi Assist teams up with LawtonAsia to bring AI-powered health-tech to Southeast Asia
Healthcare | March 03, 2026

Medi Assist teams up with LawtonAsia to bring AI-powered health-tech to Southeast Asia

The collaboration will leverage Medi Assist’s proprietary technology to streamline claims processing, enhance transparency, and deliver smarter health benefits to policyholders in the region


JB Pharma Q3 FY26 PAT up by 22% to Rs. 198 Cr
News | January 18, 2026

JB Pharma Q3 FY26 PAT up by 22% to Rs. 198 Cr

The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26


JB Pharma Q2 PAT up 19 % at Rs. 208 Cr
News | November 12, 2025

JB Pharma Q2 PAT up 19 % at Rs. 208 Cr

Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore


Torrent Pharma to acquire KKR’s stake in JB Pharma for Rs. 25,689 Cr
News | June 29, 2025

Torrent Pharma to acquire KKR’s stake in JB Pharma for Rs. 25,689 Cr

Acquisition to be followed by merger; strengthens Torrent’s IPM market presence


JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25
News | May 16, 2025

JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25

Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25


JB Pharma reports revenue growth of 14% in Q3 FY25; Net profit up by 22%
News | February 06, 2025

JB Pharma reports revenue growth of 14% in Q3 FY25; Net profit up by 22%

Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24


Budget 2025: Industry welcomes customs duty exemptions on 36 life-saving drugs and medicines
Policy | February 01, 2025

Budget 2025: Industry welcomes customs duty exemptions on 36 life-saving drugs and medicines

The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25


JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
News | November 07, 2024

JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr

JB’s domestic business continued to out-perform the market with all our major brands posting strong growth


JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr
News | August 08, 2024

JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr

Expect the international business including CDMO business to pick-up in the second half of the financial year